drugset
drugset / Trial / NCT05409911

A Study to Assess S-217622 in Participants With Mild and Moderate Hepatic Impairment and Healthy Control Participants

NCT05409911 ↗

Phase 1 Completed 25 enrolled Shionogi
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The objective of this study is to assess the pharmacokinetics (PK), safety, and tolerability of S-217622 in participants with mild and moderate hepatic impairment compared with control participants with normal hepatic function.

Timeline

Start
2022-09-13
Primary completion
2023-04-25
Completion
2023-04-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Ensitrelvir Small molecule — Oral

Indications

No indication recorded.